Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study Post author:Sam Post published:March 11, 2018 Post category:BioPharma Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study. Source: BioSpace You Might Also Like Biogen Faces Biggest One-Day Drop March 16, 2017 Motif BioSciences, Inc. Reports Half-Year 2017 Financial Results And Operational Progress September 28, 2017 Despite Expansion Overall, Roche Diabetes Care Lays Off 157 March 14, 2017
Motif BioSciences, Inc. Reports Half-Year 2017 Financial Results And Operational Progress September 28, 2017